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Abstract 
Objective: The Beaumont Behavioural Inventory (BBI) is a behavioural proxy report for the 
assessment of behavioural changes in ALS. This tool has been validated against the FrSBe, a 
non-ALS specific behavioural assessment, and further comparison of the BBI against a disease-
specific tool was considered. This study cross-validates the BBI against the ALS-FTD-Q.  
Methods: 60 ALS patients, 8% also meeting criteria for FTD, were recruited. All patients were 
evaluated using the BBI and the ALS-FTD-Q, completed by a carer. Correlational analysis was 
performed to assess construct validity. Precision, sensitivity, specificity and overall accuracy 
of the BBI, when compared to the ALS-FTD-Q, were obtained.  
Results: The mean score of the whole sample on the BBI was 11.45±13.06. ALS-FTD patients 
scored significantly higher than non-demented ALS patients (31.6±14.64, 9.62±11.38; 
p<.0001). A significant large positive correlation between the BBI and the ALS-FTD-Q was 
observed (r=.807, p<.0001), and no significant correlations between the BBI and other 
clinical/demographic characteristics, indicating good convergent and discriminant validity, 
respectively. 72% of overall concordance was observed. Precision, sensitivity and specificity 
for the classification of severely impaired patients were adequate. However, lower concordance 
in the classification of mild behavioural changes was observed, with higher sensitivity using 
the BBI, most likely secondary to BBI items which endorsed behavioural aspects not measured 
by the ALS-FTD-Q.  
Discussion: Good construct validity has been further confirmed when the BBI is compared to 
an ALS-specific tool. Furthermore, the BBI is a more comprehensive behavioural assessment 
for ALS, as it measures the whole behavioural spectrum in this condition.  
Keywords: ALS, Behaviour, Validation, BBI, ALS-FTD-Q 
Introduction  
The notion of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) as 
two extremes of the same disease continuum [1] has offered a better understanding of the 
clinical overlap between these conditions. Behaviour changes are a frequent and significant 
presentation in ALS, and behavioural assessments are fundamental in routine 
neuropsychological evaluations in this population. To this end, the Beaumont Behavioural 
Inventory (BBI) [2] was developed. The BBI is a 41-item, self-explanatory, proxy-report 
behavioural assessment, specifically developed for use in ALS patients as it considers the 
whole spectrum of behavioural changes that can occur in this condition. Moreover, the BBI 
accounts for the confounding effects of motor dysfunction on behaviour. The BBI has 
demonstrated high internal consistency (Cronbach’s alpha=0.906) [3], and adequate 
convergent and discriminant validity (refer to [2] for tool development and validation details). 
The BBI cut-off scores (≥7 for mild behaviour changes, and ≥23 for severe behaviour changes) 
have high sensitivity and specificity, when validated against another behavioural tool, the 
Frontal System Behaviour Scale (FrSBe) [4]. Nonetheless, the use of the FrSBe as the gold 
standard to capture behavioural deficits in ALS raises concerns regarding the possibility of 
overestimating the presence of such deficits, as this tool does not correct for the effects of motor 
involvement in behaviour. Thus, there is a need to further compare the BBI against another 
ALS-specific tool that controls for such confounding effects.  
Here we cross-validate the BBI against the ALS-FTD-Q [5], with the aim of comparing these 
two disease-specific measures and explore their ability to capture the entire spectrum of 
behavioural changes in ALS.  
Methods 
Participants and assessment procedures 
Based on EMGO+ guidelines for the validation of measurement tools [6], 60 consecutive 
patients fulfilling El Escorial criteria [7] for the diagnosis of ALS and attending the MND 
National Clinic in Beaumont Hospital were recruited. Exclusion criteria included history of 
neurological, psychiatric or medical conditions other than ALS that can cause cognitive and 
behavioural changes. 5 participants (8%) from this cohort also met criteria for the diagnosis of 
behavioural variant FTD [8].  
All patients meeting inclusion criteria were assessed in one of their clinic visits. Thus, the main 
carer accompanying the patient was asked to complete the BBI and the ALS-FTD-Q. Carers 
completing the forms included spouses (58%), children (30%), siblings (7%), and other (5%; 
granddaughter, friend and brother-in-law). The revised ALS functional rating scale (ALSFRS-
R) [9] was also completed in a subset of patients (n=20) to assess disease severity. 
Demographic and clinical characteristics were acquired from the Irish ALS register [10].    
This study is part of a broader population-based study of cognition in ALS, for which full 
approval from the Beaumont Hospital Ethics Committee was attained.    
Statistical Analyses 
The Bland-Altman measure of agreement was used to determine the appropriateness of sample 
size [11]. Assuming a sample size n=60, the formula for the confidence interval for the 95% 
limits of agreement was implemented: 𝐶𝐼 =  ± 1.96√
3
𝑛
𝑠. Assumption of normality of 
individual differences between ALS-FTD-Q and BBI was calculated using the formula: ?̅? ±
 1.96𝑠.  
Descriptive statistics are presented in terms of means and standard deviations (sd) for 
quantitative data, and in number of cases (n) and percentage (%) for count data. All group 
comparisons were performed using non-parametric methods (Independent Samples Mann-
Whitney U Test), as assumption of normal distribution for all samples could not be assumed.  
Correlational analysis was performed between the BBI and the ALS-FTD-Q to assess construct 
validity (convergent validity), and between the BBI and other clinical and demographic 
components (age, years of education, age at onset, age at diagnosis, diagnostic delay and 
ALSFRS-R) to assess discriminant validity.  
Precision, sensitivity and specificity of the BBI in comparison to the ALS-FTD-Q were 
calculated. Accuracy or overall correctness was also obtained. To do so, the following formulae 
were applied:  
 Precision or consistency between tests = True Positives / (True Positives + False Positives) 
 Sensitivity or true-positives rate = True Positives / (True Positives + False Negatives) 
 Specificity or true-negatives rate = True Negatives / (True Negatives + False Positives) 
 Accuracy or correct classifications = True Positives / Total Observations 
Behavioural changes on the BBI are assessed on a 3-point rating scale (0 - No Changes, 1 - 
Mild, 2 - Moderate, and 3 - Severe), and the score ranges from 0 to 123. On the other hand, the 
presence of behavioural changes on the ALS-FTD-Q is graded on a 4-point scale (0 - 
Completely disagree/Never, 1 - Largely disagree/Sometimes, 3 - Largely agree/Often, and 4 - 
Completely agree/Always), and the maximum score is 100. Thus, on both measures, the higher 
the score, the higher the presence of behavioural change. For the ALS-FTD-Q, the cut-off for 
mild disturbances is considered at ≥22, and for severe disturbances, at ≥29 [5]. The BBI cut-
offs are ≥7 for mild changes, and ≥23 for severe changes [2].  
IBM Statistical Package for the Social Sciences (SPSS) 22.0 was used for analyses. 
 
Results  
Sample size adequacy was assessed by calculating the limits of agreement, as per Bland and 
Altman [11]. A normal distribution within individual’s measurements differences was 
assumed: ?̅? ±  1.96𝑠 =  −15.435 𝑎𝑛𝑑 17.565 (see Figure 1).  95% limits of agreement using 
a sample size of 60 participants were as follows: 𝐶𝐼 =  ± 1.96√
3
60
8.25 = −3.62 𝑎𝑛𝑑 3.62. 
Thus, a sample size of 60 gives a CI of +-0.44*s, which is a low limit of agreement, robust 
enough to detect differences between measures.  
FIGURE 1 HERE 
 
Figure 1. Bland-Altman Plot of within individual’s measurements differences 
 
Table 1 summarizes demographic and clinical characteristics of the sample. 
[TABLE 1 HERE] 
Table 1. Demographic and Clinical Characteristics of the Patient Sample 
 
Patient 
Group 
n = 60 
ALS  
n = 55 
ALS-FTD  
n = 5 
Gender 
n(%) 
Males 42 (70%) 38 (69) 4 (80) 
Females 18 (30%) 17 (31) 1 (20) 
Age mean(sd) 65.42 (9.72) 65.18 (9.85) 68.00 (8.69) 
Years of Education mean(sd) 13.2 (3.42) 13.29 (3.5) 12.20 (2.39) 
Age at Onset mean(sd) 63.42 (9.35) 63.30 (9.55) 64.80 (7.56) 
Site of 
onset 
n(%) 
Spinal 38 (64%) 34 (62) 4 (80) 
Bulbar 17 (28%) 16 (29) 1 (20) 
Thoracic/Respiratory 5 (8%) 5 (9) 0 
Age at Diagnosis mean(sd) 64.68 (9.51) 64.42 (9.66) 67.60 (7.89) 
Diagnosis Delay, in months 
mean(sd) 
15.37 (11.69) 14.18 (10.20) 28.40 (19.49) 
ALSFRS-R mean(sd) 
n= 20 n = 17 n = 3 
33.4 (6.18) 32.18 (5.78) 40.33 (3.21) 
 
Considering that the ALSFRS-R was available only for a proportion of the total sample, 
comparability of the subset of patients that had an ALSFRS-R (n=20) and the subset that had 
not (n=40) was examined. No significant differences between the two subsamples was 
observed in terms of demographic or clinic characteristics: (Age: ALS-FRS-R = 66.80±8.28, 
ᴓALS-FRS-R = 64.73±10.39; p=.354. Education: ALSFRS-R = 13.03±3.61, ᴓALS-FRS-R = 
13.29±3.36; p=.950. Age at onset: ALSFRS-R = 64.53±7.88, ᴓALS-FRS-R = 62.90±10.02; 
p=.431. Age at diagnosis: ALSFRS-R = 65.90±8.21, ᴓALS-FRS-R = 64.07±10.14; p=.441. 
Diagnostic delay: ALSFRS-R = 20.40±15.28, ᴓALS-FRS-R = 12.85±8.57; p=.104). 
Regarding behavioural measures, the mean score for the BBI was 11.45±13.06, and 
14.35±13.43 for the ALS-FTD-Q. When the sample was divided between patients meeting 
criteria for the diagnosis of ALS-FTD and ALS patients without dementia, ALS-FTD patients 
scored significantly higher on both the BBI (ALS-FTD=31.6±14.64, ALS=9.62±11.38; 
p<.0001) and the ALS-FTD-Q (ALS-FTD=34.8±10.33, ALS=12.49±12.12; p=.002).  
Group comparisons on behavioural measures between patients that had an ALSFRS-R (n=20) 
and patients for whom this was not available (n=40) were also performed. No significant 
difference was observed on the ALS-FTD-Q (ALS-FRS-R = 18.20±14.42, ᴓALS-FRS-R = 
12.43±12.65; p=.074), although a significant difference was found on the BBI (ALSFRS-R = 
16.25±14.29, ᴓALS-FRS-R = 9.05±11.88; p=.040). Considering that the majority of ALS-FTD 
participants are included in the group that had an ALS-FRS-R performed, and this is likely to 
have had an effect on these results, this analysis was carried out excluding all ALS-FTD cases. 
Results indicated that no significant difference existed on the BBI between patients who had 
ALSFRS-R and patients who did not (ALSFRS-R = 13.64±12.34, ᴓALS-FRS-R = 7.82±10.61; 
p=.076).  
Regarding correlational analysis, a significant large positive correlation was observed between 
the BBI and the ALS-FTD-Q total scores (r=.807, p<.0001). No significant associations were 
observed between the BBI and most demographic and clinical measures: age (r=-.074, p=.576), 
education (r=-.077, p=.558), age at onset (r=-.100, p=.450), age at diagnosis (r=-.066, p=.615), 
and ALS-FRS-R (r=-.014, p=.954); or between most clinical/demographic characteristics and 
the ALS-FTD-Q: age (r=-.175, p=.181), education (r=-.153, p=.244), age at onset (r=-.216, 
p=.101), age at diagnosis (r=-.108, p=.169), ALS-FRS-R (r=-.049, p=.838). Nevertheless, a 
significant positive medium correlation was observed between diagnostic delay and the BBI 
(r=.405, p=.001), as well as between diagnostic delay and the ALS-FTD-Q (r=.319, p=.013). 
This relationship was further explored. Considering the longer diagnostic delay in the ALS-
FTD group compared to the ALS group, ALS-FTD patients were removed from the analysis, 
and at that point the correlations did not reach statistical significance: BBI (r=.197, p=.149), 
ALS-FTD-Q (r=.221, p=.104). 
Cross-tabulated data for the BBI and ALS-FTD-Q is presented in Table 2. Precision, sensitivity 
and specificity for each diagnostic category, as well as overall accuracy are presented in Table 
3.  
[TABLE 2 HERE] 
[TABLE 3 HERE] 
Table 2. BBI and ALS-FTD-Q cross-tabulations 
 
BBI 
Normal Mild Severe Total 
ALS-FTD-Q 
Normal 32 13 1 46 
Mild 0 3 3 6 
Severe 0 0 8 8 
Total 32 16 12 60 
 
 
Further exploratory analysis was performed. In cases where the BBI seemed to overestimate 
the behavioural categorization when compared to the ALS-FTD-Q, items more frequently 
endorsed within this sub-cohort (n=17) were investigated. Items for which some degree of 
change was indicated by more than half of the subsample (>8 participants) were considered as 
frequently endorsed.  
Two items from the BBI were endorsed by most caregivers in this subset of the sample: a social 
cognitive item (‘diminished social interest’) and an apathy item (‘loss of motivation for 
previous interests’). Within the behaviour category Loss of sympathy or empathy from the 
revised diagnostic criteria for bvFTD [8], the ALS-FTD-Q assesses the item ‘diminished 
Table 3. Precision, sensitivity, specificity and accuracy of the BBI in comparison to the 
ALS-FTD-Q 
 Normal Mild Severe 
Precision 100 19 67 
Sensitivity 70 50 100 
Specificity 100 76 92 
Overall Accuracy 72 
responsiveness to other people’s needs and feelings’, but it does not assess ‘general decline in 
social engagement’, which is indeed assessed by the BBI. In terms of apathy, the ALS-FTD-Q 
includes two items: ‘less interest in surroundings’ and ‘display of more withdrawn behaviour’. 
The BBI, on the other hand, includes an apathy item which is more specific to loss of interest 
in previous rewarding activities. To assess reliability of apathy measurement within the two 
scales, correlational analysis was performed between the apathy items on the ALS-FTD-Q and 
the highly endorsed apathy item on the BBI (‘loss of interest in previous interests’). Spearman's 
rank correlation coefficients were calculated, and no significant findings were observed: ‘less 
interest in surroundings’ (rho=.252; p+=.330); ‘display of more withdrawn behaviour’ 
(rho=.285; p=.267). 
Other behavioural aspects that were frequently endorsed (by 7/8 participants) by this subcohort 
of patients who were classified as abnormal on the BBI but as normal on the ALS-FTD-Q 
(n=17),  included ‘distractibility’, ‘inappropriate emotional display’, ‘increased sensitivity to 
sensations such as touch, noise, heat, cold, taste or pain’, and ‘increased occurrence of 
grammatical mistakes’. Although decreased concentration and impaired emotional stability are 
assessed by the ALS-FTD-Q, this does not assess altered responses to sensory stimuli or 
cognitive changes related to language. 
 
Discussion  
The BBI, an ALS-specific behavioural scale, has been further validated against another 
disease-specific behavioural instrument, the ALS-FTD-Q. BBI scores highly correlated with 
ALS-FTD-Q scores, but were independent of other clinical and demographic measures such as 
age, years of education, age at onset, age at diagnosis and ALSFRS-R. Thus, the current cross-
validation of the BBI has confirmed adequate convergent and discriminant validity. 
Nonetheless, when performing correlational analysis, a significant positive medium correlation 
between the degree of behavioural change on both the BBI and the ALS-FTD-Q, and diagnostic 
delay was observed. A possible explanation for this observation is that three out of the five 
ALS-FTD patients in this sample experienced cognitive/behavioural changes before or at the 
same time as the motor symptoms, which would have prompted a diagnosis of FTD, and 
delayed the diagnosis of ALS. This proposition was supported by the longer diagnostic delay 
of the ALS-FTD group, compared to the ALS group. So, with this hypothesis in mind, 
correlational analysis was repeated excluding the ALS-FTD sub-cohort, and no significant 
correlations between behavioural changes and diagnostic delay were further observed. 
The original BBI validation established a cut-off of ≥7 for mild behavioural changes (88% 
sensitivity and 79% specificity), and ≥23 for severe behavioural changes (90% sensitivity and 
96% specificity). Considering these cut-offs, 47% of the ALS sample presented with 
behavioural changes. When compared to the ALS-FTD-Q, classification assessment indicated 
that a cut-off of ≥23 on the BBI is adequate for the diagnosis of severe behavioural changes 
(Precision=67; Sensitivity=100; Specificity=92). A cut-off of ≥7 showed limited accurateness 
in diagnosing mild behavioural changes (Precision=19). However, further investigation of 
items endorsed by ‘over categorized’ participants on the BBI showed that most of these items 
assess behavioural aspects not measured by the ALS-FTD-Q. Among them, a general decline 
in social engagement, a loss of interest in previously rewarding interests, higher sensitivity to 
sensory stimuli, and the presence of more grammatical mistakes outstand. Thus, significant 
behavioural aspects in ALS such as diminished social interest or an altered response to sensory 
stimuli are not measured by the ALS-FTD-Q. Moreover, the ALS-FTD-Q incorporates 
cognitive items that focus solely on executive function, and do not take language changes into 
account. Finally, although the ALS-FTD-Q measures apathy, correlations between apathy 
items on the ALS-FTD-Q and the BBI were not significant, indicating that such items assess 
different aspects of apathy, and the BBI item ‘loss of motivation for previous interests’ seems 
to be more sensitive to capture changes.  
In conclusion, cross-validation of the BBI against the ALS-FTD-Q has shown that the BBI is 
more sensitive to mild behavioural changes in ALS, as it assesses the entire behavioural 
spectrum observed in this condition. These data confirm that the BBI is a robust and 
psychometrically sound tool for the assessment of behavioural changes in ALS. Further cross-
sectional and longitudinal population-based studies with large incident samples are needed to 
confirm the prevalence of behavioural changes in ALS using this new behavioural measure.  
 
Author Contributions 
MPG contributed to the process of data collection, data entry, analysed the data and wrote the 
manuscript; EC contributed to the process of data entry, data analysis and revised the 
intellectual content of the manuscript; SOC contributed to the process of data collection, and 
revised the intellectual content of the manuscript; ME and TB revised the intellectual content 
of the manuscript; MH administered the management aspects and revised the intellectual 
content of the manuscript; NP supervised the neuropsychological aspects of the study and 
revised the manuscript from a neuropsychological perspective; and OH supervised all clinical 
aspects of the study in all stages of development and revised the manuscript from a clinical 
perspective.  
Acknowledgements 
This research has received funding from the Health Seventh Framework Programme 
(FP7/2007-2013) under grant agreement n° 259867, ALSA (the ALS Association),  HRB (the 
Health Research Board, grant H01300), Joint Programme in Neurodegeneration  (JPND), The 
Irish Institute of Clinical Neuroscience (grant 12549.201616) and Research  Motor Neuron 
(previously named Motor Neuron Disease Research Foundation). 
Conflicts of Interest   
Ms. Marta Pinto-Grau, Mr Emmet Costello, Ms Sarah O’Connor, Dr Marwa Elamin, Dr Tom 
Burke, Mr Mark Heverin, and Prof. Niall Pender have nothing to disclose.  
Prof. Orla Hardiman has received fees for consultation work from Biogen Idec, Cytokinetics 
and Novartis. She serves as Editor-in-Chief of Amyotrophic Lateral Sclerosis. The authors 
report no conflict of interests.     
 
References  
1. Burrell JR, Halliday GM, Kril JJ, Ittner LM, Götz J, Kiernan MC, Hodges JR. The 
frontotemporal dementia-motor neuron disease continuum. The Lancet. 2016; 388:919-
31. 
2. Elamin M, Pinto-Grau M, Burke T, Bede P, Rooney J, O’Sullivan M, Lonergan K, 
Kirby E, Quinlan E, Breen N, Vajda A, Heverin M, Pender N, Hardiman O. Identifying 
behavioural changes in ALS: Validation of the Beaumont Behavioural Inventory (BBI). 
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2016; 18: 68-73 
3. Burke T, Pinto-Grau M, Lonergan K, Bede P, O’Sullivan M, Heverin M, Vajda A, 
McLaughlin R, Pender N, Hardiman O. A Cross-Sectional population-based 
investigation into behavioural changes in Amyotrophic Lateral Sclerosis: 
subphenotypes, staging, cognitive predictors, and survival. Annals of Clinical and 
Translational Neurology. 2017; doi: 10.1002/acn3.407 
4. Grace J, Malloy PF. Frontal Systems Behavior Scale: FrSBe. Psychological 
Assessment Resources; 2001. 
5. Raaphorst J, Beeldman E, Schmand B, Berkhout J, Linssen WH, van den Berg LH, 
Pijnenburg YA, Grupstra HF, Weikamp JG, Schelhaas HJ, Papma JM. The ALS-FTD-
Q A new screening tool for behavioral disturbances in ALS. Neurology. 2012; 
79(13):1377-83. 
6. Questionnaires: selecting, translating and validating [Internet]. The Netherlands: 
Institute for Health and Care Research [2010]. Available from: 
http://www.emgo.nl/kc/preparation/research%20design/8%20Questionnaires%20selec
ting,%20translating%20and%20validating.html. 
7. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for 
the diagnosis of amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis and other 
motor neuron disorders. 2000;1(5):293-9. 
8. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van 
Swieten JC, Seelaar H, Dopper EG, Onyike CU, Hillis AE. Sensitivity of revised 
diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011; 
134(9):2456-77. 
9. Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional 
rating scale that incorporates assessments of respiratory function. BDNF ALS Study 
Group (Phase III). J Neurol Sci. 1999; 169(1-2):13-21. 
10. Rooney J, Byrne S, Heverin M, Corr B, Elamin M, Staines A, Goldacre B, Hardiman 
O. Survival analysis of Irish amyotrophic lateral sclerosis patients diagnosed from 
1995–2010. PloS one. 2013; 8(9):e74733. 
11. Bland JM, Altman DG. Statistical methods for assessing agreement between two 
methods of clinical measurement. International Journal of Nursing Studies. 2010 Aug 
31;47(8):931-6. 
 
